B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

HTR1F

MOLECULAR TARGET

5-hydroxytryptamine receptor 1F

UniProt: P30940NCBI Gene: 6044821 compounds

HTR1F (5-hydroxytryptamine receptor 1F) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HTR1F

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Sumatriptan2.5612
2Metergoline2.087
3Methysergide1.956
4Dihydroergotamine1.614
5Ergotamine1.614
6Yohimbine1.614
7Mianserin1.102
8Quetiapine Fumarate1.102
9brl 155721.102
10Mescaline Hallucinogenic alkaloid isolated from1.102
11Methylergonovine1.102
12Pergolide1.102
13Fluoxetine0.691
14Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent0.691
15Bufotenin0.691
16Cyproheptadine0.691
17Metoclopramide0.691
18Nortriptyline0.691
19Pindolol0.691
20Quipazine0.691
21Tamsulosin0.691

About HTR1F as a Drug Target

HTR1F (5-hydroxytryptamine receptor 1F) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented HTR1F interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HTR1F inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.